Litcius/Paper detail

Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19

D Praveen, Ranadheer Chowdary Puvvada, M. Vijey Aanandhi

2020International Journal of Antimicrobial Agents95 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)RepurposingPandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Ideal (ethics)2019-20 coronavirus outbreakMedicineVirologyDrug repositioningOutbreakIntensive care medicineDrugDiseasePharmacologyBiologyPolitical scienceInternal medicineEcologyInfectious disease (medical specialty)LawSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVenomous Animal Envenomation and Studies
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19 | Litcius